SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

NEXT STORY
Interpace to Present at the American College of Gastroenterology Conference
PREV STORY
Global Healthcare-associated Infectious (HAI) Disease Diagnostics Market Outlook, 2019-2024 – High Growth Potential in Low & Middle-income Countries
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily

SB206 12% once-daily achieved the highest rate of complete clearance out of all active ...

author_avatar
NASDAQ Market News

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests

author_avatar
NASDAQ Market News

Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)

author_avatar
NASDAQ Market News